Alpha-Galcer (KRN7000) used in hepatic research

Innate Immunity Drives Xenobiotic-Induced Murine Autoimmune Cholangitis

Antitumor immunity produced by the liver Kupffer cells, NK cells, NKT cells, and CD8 CD122 T cells

Abnormal Changes in NKT Cells, the IGF-1 Axis, and Liver Pathology in an Animal Model of ALS

Natural killer T cells activated by a lipopeptidophosphoglycan from Entamoeba histolytica are critically important to control amebic liver abscess

Targeting the diverse immunological functions expressed by hepatic NKT cells

TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells

Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer

Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection

α-Galactosylceramide activates antitumor immunity against liver tumor

Protective Role of Interleukin-17 in Murine NKT Cell-Driven Acute Experimental Hepatitis

Sulfatide-Mediated Activation of Type II Natural Killer T Cells Prevents Hepatic Ischemic Reperfusion Injury In Mice

Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance

Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice

SOCS3 in T and NKT cells negatively regulates cytokine production and ameliorates ConA-induced hepatitis

Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation

Suppression of Con A-induced hepatitis induction in ICOS-deficient mice

Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors

Preactivation of NKT cells with Alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor

Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment

Antitumor Effect of Alpha-Galactosylceramide (KRN7000) on Spontaneous Hepatic Metastases Requires Endogenous Interleukin 12 in the Liver

KRN7000 in Chronic Hepatitis B

Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection

Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000

Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer

Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production

Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor

Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with alpha-Galactosylceramide

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer

Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice

CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver

Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells

Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro

α-Galactosylceramide and Novel Synthetic Glycolipids Directly Induce the Innate Host Defense Pathway and Have Direct Activity against Hepatitis B and C Viruses

Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor

Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C

Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide

Injection of the immuno-modulatory drug alpha-galactosylceramide results in the recruitment of a large population of antigen-presenting cells into the liver of C57BL/6 mice

Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide

Role of Valpha 14 NKT cells in the development of impaired liver regeneration in vivo

NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells

CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver

Back to top

 

New 7DW8-5 glycolipid

7DW8-5

Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch

 

Meet Funakoshi Company
at the following meetings:

NIH Festival
Bethesda, Maryland
September 14-15, 2017

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

ASCB
Philadelphia, PA
December 2-6, 2017